A major Novartis shareholder’s demand for board changes after back-to-back clinical setbacks has turned the company’s pipeline disappointment into a broader governance warning for large drugmakers that increasingly rely on acquired biotech assets for growth.
Artisan Partners’ David Samra, whose firm is among Novartis’ top 20 investors, called for changes to the Swiss drugmaker’s board, stronger acquisition oversight and a board-level acquisition committee after a late-stage failure in a muscle-wasting disorder drug tied to Novartis’ $12 billion Avidity takeover helped trigger a record share-price fall, Reuters reported on September 10.1 A syndicated Reuters version said Samra urged Chairman Giovanni Caforio to strengthen acquisition oversight and add directors focused on deal scrutiny.2
The immediate issue is Novartis. The larger issue is whether boards at global pharmaceutical companies have governance systems explicit enough for a strategy in which bolt-on biotech deals, not just internal research, are expected to replenish pipelines and sustain growth.
Novartis said its financial guidance was unchanged by the setbacks and pointed to a broad medicines pipeline. It also said it follows a disciplined, shareholder-friendly capital allocation strategy that includes organic investment, bolt-on deals, dividends and buybacks.1
But Artisan’s intervention shows how quickly a failed trial readout can become a board accountability issue when investors believe the science was bought at a premium and board-level diligence did not adequately protect capital.
From clinical risk to governance risk
Drug development failure is not unusual. Late-stage clinical trials can miss endpoints even when earlier data appear compelling.
What has changed is the governance context. Large drugmakers are paying substantial sums for biotech assets that may still depend on a small number of pivotal data events.
In Novartis’ case, Reuters reported that the Avidity-linked muscle-wasting disorder drug failed a late-stage study, sending shares down more than 10% and erasing nearly $30 billion in market value.1 MarketScreener’s Reuters syndication also noted that Novartis shares had fallen a day earlier after disappointing results for heart drug pelacarsen, compounding investor concern.2
Pharmaceutical Executive reported that the two readouts drove an approximately 13% two-day decline and framed Samra’s criticism as a direct challenge to Novartis’ board governance, deal approval process and compensation design.3 Investing.com separately reported that HSBC upgraded Novartis to Hold from Reduce after the back-to-back pelacarsen and del-desiran failures, saying the negative catalyst path had largely played out while investor focus shifted to another upcoming trial readout.8
That analyst reaction underscores the core tension for pharma boards. Markets may eventually reprice after a catalyst failure, but governance questions can persist if investors conclude that repeated setbacks reflect poor acquisition discipline rather than normal portfolio volatility.
The acquisition committee question
Samra’s most pointed proposal was structural: create a board-level acquisition committee and bring in directors with stronger deal oversight capabilities.1 The recommendation matters beyond Novartis because many large pharma boards approve transactions that combine three difficult judgments: scientific probability, commercial opportunity and capital allocation.
Traditional board review often emphasizes valuation, strategic fit and management’s diligence process. In biotech acquisitions, however, the key value driver may be a narrow scientific hypothesis, a trial design assumption or a regulatory pathway that can unravel quickly.
Artisan’s critique suggests investors may increasingly expect boards to show not only that management performed diligence, but that directors had the expertise and process to challenge it.
Pharmaceutical Executive reported that Artisan also pointed to Novartis’ 2024 acquisition of MorphoSys as a cautionary example, saying investor confidence faded after the company wrote down acquisition value within months.3 Reuters likewise reported that Samra cited MorphoSys as part of a broader critique of Novartis’ acquisition track record.1
For healthcare dealmakers, the message is that bolt-on does not mean low-risk. A transaction may be smaller than a transformational merger but still large enough to affect investor trust if the lead asset fails or is written down soon after closing.
Compensation enters the debate
The backlash also reached executive pay. Samra urged Novartis to overhaul compensation metrics that he said rely too heavily on adjusted measures excluding writedowns, rather than reflecting real economic outcomes.1 Bloomberg Law’s pickup of the Reuters report emphasized the financial-accounting relevance of the demand, including the call for an M&A revamp and accountability after clinical-trial failures.4
That critique is significant because acquisition discipline is not only a matter of who approves deals. It also depends on whether pay structures reward revenue growth, adjusted earnings and pipeline expansion while insulating decision-makers from the economic consequences of unsuccessful transactions.
Boards may face growing pressure to link deal outcomes to longer-term incentives, especially when acquired assets are central to medium-term growth targets. That could include post-deal performance scorecards, explicit treatment of impairments in compensation calculations, or deferred incentives tied to clinical, regulatory and commercial milestones.
A signal to pharma boards
Artisan is the first investor to publicly call for Novartis board changes, Reuters reported, although other investors have raised concerns about the company’s M&A strategy.1 Whether that pressure spreads will depend partly on Novartis’ next pipeline catalysts and partly on how the board responds.
For pharma boards, the lesson is broader than one failed study. As patent expirations, pricing pressure and competition increase the need for external innovation, acquisition governance is becoming part of pipeline governance.
Directors may need to demonstrate that they can independently test management’s scientific assumptions, understand concentration risk in acquired portfolios and set consequences when capital allocation fails.
The Novartis episode shows that when growth depends on bought science, trial failures do not stop at the R&D committee. They can reach the boardroom.
Comments